- ¥123bn
- ¥159bn
- ¥30bn
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Nxera Pharma Submits Marketing Authorization Application For Daridorexant In South Korea
Table: Nxera Pharma -2025 parent results
Table: Nxera Pharma -2025 group results (IFRS)
Brief: Nxera Pharma Reports Positive Results From Phase 3 Trial Of Daridorexant In South Korea
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Nxera Pharma To Regain Full Rights To Gpr52 Agonist Program For Schizophrenia
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma Says Workforce Reduction Of About 15% Across Japan & UK Operations
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Table: Nxera Pharma -9-MTH group results (IFRS)
Table: Nxera Pharma 6-MTH group results (IFRS)
Nxera Launches Broad Proprietary Pipeline Targeting Obesity And Chronic Weight Management
Nxera To Receive Us$4.8 Mn In Milestone Payments Following Centessa's Initiation Of Clinical Development Of Orx142, A Novel Ox2r Agonist
Nxera Pharma Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases
Brief: Nxera Pharma Says Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up